GLENMARK PHARMACEUTICALS LTD. - 532296 - Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 26, 2020, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2019 - 20 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
Glenmark Pharma Q4 net profit jumps 36% to Rs 220 crore
The company's consolidated revenue for the quarter rose 7.96 per cent to Rs 2,767.48 crore as against Rs 2,563.47 crore a year ago, Glenmark Pharmaceuticals said in a regulatory filing. GLENMARK PHARMACEUTICALS LTD. - 532296 - Audited Financial Results For The Year Ended March 31, 2020
Outcome of the Board Meeting - June 26, 2020 A.The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on June 26, 2020, which commenced at 05.00 p.m. and concluded at 8.40 p.m., considered and approved the following: 1.Audited Financial Results for the year ended March 31, 2020. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com 2.Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2019 - 20 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
Buy Glenmark Pharma; target of Rs 488: ICICI Securities
ICICI Securities is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 488 in its research report dated June 22, 2020.
Glenmark's Fabiflu is first in the market, but has limited growth opportunity
The drug is priced at 103 per tablet, while Glenmark has the first-mover advantage.Incremental revenues of Rs200 crore-300 crore could accrue, say some analysts, although it's more of a guesstimate given the many variables
Glenmark shares hit 15% upper circuit after regulator's nod for COVID-19 drug
The pharma company said that it has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections . Early clinical trial results of Favipiravir for Covid-19 promising : Glenmark
Indian pharma major Glenmark has stated that its phase three clinical trials using antiviral drug Favipiravir for Covid-19 patients is showing early GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Unlocks The Treatment For Mild To Moderate Covid-19 In India
Glenmark unlocks the treatment for Mild to Moderate Covid-19 in India GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Becomes The First Pharmaceutical Company In India To Receive Regulatory Approval For Oral Antiviral Favipiravir, For The Treatment Of Mild To Moderate COVID-19
Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19